Dr. Edward (Ed) Greenfield, PhD, is a renowned expert in antibody discovery and development. He has more than 30 years of experience in small biotech startups and large biopharmaceutical companies. Previously, Dr. Greenfield has held significant leadership positions, including directing antibody technology at Repligen Corporation (NASDAQ) from 1992 to 1995, Millennium Pharmaceuticals (2001-2007), acquired by Takeda for $8.7 billion, and at Abpro, an antibody biotech company that went public in 2023 after merging with Atlantic Coastal Acquisition Corp. He served as the Director of the Monoclonal Antibody Core at Dana-Farber Cancer Institute (1995-2001; 2008-2020) and now holds the same position at Brigham and Women’s Hospital, a key component of Mass General Brigham. He is an inventor of several patents in monoclonal antibody development and the author of the book Antibodies: A Laboratory Manual (Second Edition, Cold Spring Harbor Press, 2005).